Filter by:
Topic
Resource Type
Audience
Display Only
Showing 72 Results
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
Predictors of Adherence to Oral Anticancer Medications: An Analysis of 2010-2018 U.S. Nationwide Claims
Low-income Medicare patients who face high out-of-pocket costs are less likely to remain adherent to oral anticancer medications. This research shows the need for strategies to address adherence and…
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Premium Impact of Expanding Pre-Deductible Coverage to Chronic Disease Management Medications in HSA-Eligible Health Plans
An NPC-funded study found the impact on premiums of expanding pre-deductible coverage to 116 drug classes related to chronic disease management medications in HSA-eligible health plans is small …
Specialty Drug and Healthcare Utilization Vary by Wage Level in Employer-Sponsored Health Plans
This research shows that low-wage employees are less likely use autoimmune medicines than employees who earn more despite a higher prevalence of autoimmune conditions in low-wage employees. These…
The Impact of Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans on Premiums
Research found that expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, while lowering costs for patients.
Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans Benefits Patients
Expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, according to a research report by the Employer Benefits Research Institute.
Pharmacists Can Help the Pharmaceutical Ecosystem Work Better for Patients
In a commentary, NPC President and CEO John O’Brien reflects on his personal experience as a pharmacist and how that training led him on the path to a career in health policy.
Innovation Matters: Changing Lives for Cystic Fibrosis Patients
In this video from NPC’s Innovation Matters series, cystic fibrosis patient advocate Katherine Fielding discusses how the invention of modulator therapies has changed her life and how more innovation…
Cost-Sharing and Adherence, Clinical Outcomes, Health Care Utilization, and Costs: A Systematic Literature Review
Higher patient cost-sharing for prescription medications leads to worse medication initiation, adherence, persistence, and discontinuation, according to a new systematic literature review by…
High Patient Out-of-Pocket Costs Lead to Worse Medication Adherence Without Overall Health Care Savings
Research from NPC and Xcenda suggests that high cost-sharing for prescription medications may have negative effects on patient health while not actually decreasing overall health care costs.
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovation Matters: Revolutionary Changes for Arthritis Patients
Anna Hyde, vice president of advocacy and access for the Arthritis Foundation, discusses how biopharmaceutical innovation has advanced the health of people living with arthritis.
Innovation Matters: The Evolution of Cancer Therapies
In this video from NPC’s Innovation Matters series, Dr. Peter Emtage describes the evolution of cancer therapies and the importance of ensuring patient access to these medicines.
Innovation Matters: The Unintended Consequences of Drug Pricing Regulation
In NPC’s Innovation Matters video series, hear from patient advocates, researchers, and other stakeholders about the potential unintended consequences for patient health if drug pricing policies harm…
Innovation Matters: Building a Healthier World
In NPC’s new Innovation Matters video series, patient advocates, researchers, and other stakeholders talk about the importance of biopharmaceutical innovation for patient health.
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Week serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies…
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
What Might Have Happened: The Impact of Interrupting Entry of Innovative Drugs on Disease Outcomes in the United States
A new NPC study shows how major drug innovations significantly improved patient health outcomes for six diseases with substantial mortality or morbidity.